Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
08/2003
08/26/2003US6610740 A nutritional, cosmetic or pharmaceutical formulation comprising esters of polyethylene glycol
08/26/2003US6610735 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide)
08/26/2003US6610718 And dosage forms for treating rheumatoid arthritis
08/26/2003US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
08/26/2003US6610673 Solid dose forms containing bismuth
08/26/2003US6610668 Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
08/26/2003US6610667 Compositions for treatment of disorders of the oesophagus
08/26/2003US6610624 Method for enhancing catalytic activity with supercritical fluids
08/26/2003US6610355 Nanostructured deposition and devices
08/26/2003US6610329 Compositions for the delivery of antigens
08/26/2003US6610328 Amoxicillin-clarithromycin antibiotic composition
08/26/2003US6610327 Oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
08/26/2003US6610326 Divalproex sodium tablets
08/26/2003US6610325 Pharmaceutical medicine comprises an iron salt, not less than two polyols, a binding agent, a lubricating agent, and a flavoring agent. The dose of elemental iron is not less than 5 mg, and preferably 10 mg to 15 mg per tablet. The polyols are
08/26/2003US6610323 An enteric coated pharmaceutical dosage form comprising an H+,K+- ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H+,K+- ATPase inhibitor to be released in at least two consecutive pulses.
08/26/2003US6610322 Liposome suspension forms spontaneously upon adding a diacylglycerol-PEG lipid to an aqueous solution when the lipid has appropriate packing parameters and the adding occurs above the melting temperature of the lipid. Combinations of lipids
08/26/2003US6610321 Emulsion formulations for hydrophilic active agents
08/26/2003US6610318 Sterile ophthalmological gel preparation applicable in drops and process for producing it
08/26/2003US6610317 Forming solution, suspension; desolventizing; spray drying
08/26/2003US6610315 Mixture of alcohol and water; presurgery scrub
08/26/2003US6610314 Comprising one or more proton donating agents and an alkyl phosphate anionic surfactant: high activity against numerous bacteria and other microorganisms
08/26/2003US6610309 Vaccines; mixture of antigen and water solubility organometallic compound
08/26/2003US6610304 Peptides having activity against HIV into liposomes of sufficient size for white blood cell internalization (e.g. greater than 150 nm and preferably approximately 250-400 nm.) has been shown to increase the activity of those MBPCs
08/26/2003US6610273 Container is provided with a non-metal interior surface so as to reduce chemical degradation
08/26/2003US6610272 Medicinal aerosol formulation comprising pioglitazone hydrochloride and a protective colloid amino acid stabilizer
08/26/2003US6610271 System and method for intranasal administration of lorazepam
08/26/2003US6610266 Calcium metasilicates and methods for making
08/26/2003US6610223 Focused acoustic energy used to eject droplet of solution which is directed into or through antisolvent that upon admixture with solution droplet causes compound in drop to precipitate; antisolvent is supercritical fluid
08/26/2003CA2420136A1 Systems and methods for remotely controlling medication infusion and analyte monitoring
08/26/2003CA2309033C Lacrimal gland specific emulsions for topical application to ocular tissue
08/26/2003CA2216780C Biological reagent spheres
08/25/2003CA2405347A1 Medicament comprising nk4 gene or recombinant nk4 protein
08/21/2003WO2003069327A1 Ion-sensitive field effect transistor and a method for producing a transistor of this type
08/21/2003WO2003068936A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003WO2003068843A1 Glucosamine-polyacrylate inter-polymer complex and applications thereof
08/21/2003WO2003068805A2 Formulation strategies in stabilizing peptides in organic solvents and in dried states
08/21/2003WO2003068722A1 Carboxylic acid compounds for use as surfactants
08/21/2003WO2003068604A1 Drug dose-form and method of manufacture
08/21/2003WO2003068315A1 A pulmonary drug delivery composition containing a progestogen and an androgen for use in a contraceptive method in males
08/21/2003WO2003068314A1 Pulmonary administration of 6-alpha-alkylated testosterone derivatives for androgen replacement therapy
08/21/2003WO2003068287A1 Compositions comprising undifferentiated fetal cells for the treatment of skin disorders
08/21/2003WO2003068281A1 Composition for skin healing comprising a chitosan hydrogel
08/21/2003WO2003068267A1 Composition for oral or rectal administration
08/21/2003WO2003068266A1 Oral solid solution formulation of a poorly water-soluble active substance
08/21/2003WO2003068264A1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
08/21/2003WO2003068260A1 Antibody-containing solution pharmaceuticals
08/21/2003WO2003068259A1 Antibody-containing solution pharmaceuticals
08/21/2003WO2003068254A1 Glycosaminoglycan-dnase combination therapy
08/21/2003WO2003068253A1 Methods and compositions for the treatment of eye diseases
08/21/2003WO2003068247A1 Eye installation based on iodine anions
08/21/2003WO2003068246A2 Improvements in or relating to compositions
08/21/2003WO2003068241A1 Percutaneous preparations
08/21/2003WO2003068239A1 Novel drugs for external use
08/21/2003WO2003068238A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
08/21/2003WO2003068216A1 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
08/21/2003WO2003068199A1 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta
08/21/2003WO2003068198A1 Adhesive sheet for promoting circulation of blood using pyroligneous liquid and method for manufacturing the same
08/21/2003WO2003068197A1 Method for systemic drug delivery through the nail
08/21/2003WO2003068196A1 Colonic release composition
08/21/2003WO2003068195A1 Oral dosage form for controlled drug release
08/21/2003WO2003068194A1 Tablets having improved tabletting characteristics and process for producing the same
08/21/2003WO2003068193A1 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
08/21/2003WO2003068192A1 Depot medicament, carrier materials for depot medicaments, and method for the production thereof
08/21/2003WO2003068191A1 Formulations of atorvastatin stabilized with alkali metal additions
08/21/2003WO2003068190A1 Intracellular delivery of therapeutic agents
08/21/2003WO2003068189A1 Lipid vesicles, production and use thereof
08/21/2003WO2003068188A1 Combination therapy for respiratory disorders
08/21/2003WO2003068187A1 Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
08/21/2003WO2003068186A1 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
08/21/2003WO2003068173A1 Micromesh interproximal devices
08/21/2003WO2003068169A2 Stabilized synthetic immunogen delivery system
08/21/2003WO2003068161A2 Composition and method for protecting labile active components
08/21/2003WO2003068145A2 Herbal immune system stimulant
08/21/2003WO2003068049A2 Controlled cerebrospinal infusion and shunt system
08/21/2003WO2003068008A1 Water-dispersible coenzyme q10 dry powders
08/21/2003WO2003067988A1 Aqueous antiseptic based on bispyridiniumalkanes
08/21/2003WO2003067952A2 Glucosamine-polyacrylate inter-polymer complex and applications thereof
08/21/2003WO2003060142A9 Compositions and methods for controlled release
08/21/2003WO2003059385A3 Hiv vaccine and method of use
08/21/2003WO2003043610A3 A process for manufacture of a sustained release composition containing microbe
08/21/2003WO2003037412A3 A device, method and resistive element for vaporising a medicament
08/21/2003WO2003030862A3 Anaesthetic compositions and method for their administration
08/21/2003WO2003020751A3 Homing peptides
08/21/2003WO2002098459A3 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
08/21/2003WO2002095027A3 Immunostimulatory oligodeoxynucleic molecules
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085384A3 Lubricious coatings for substrates
08/21/2003WO2002085311A3 Hcg formulation
08/21/2003WO2002078567A3 Prosthetic foot with tunable performance
08/21/2003WO2002067770B1 Implantable device using ultra-nanocrystalline diamond
08/21/2003WO2002053174A3 Controlled release pharmaceutical systems
08/21/2003WO2001097753A3 Novel methods using pyridine derivatives
08/21/2003US20030158860 Method of automatically populating contact information fields for a new contact added to an electronic contact database
08/21/2003US20030158598 System for sustained-release delivery of anti-inflammatory agents from a coated medical device
08/21/2003US20030158302 Liquid component of polycationic polymer such as chitosan, and an organic monophosphate source; solid component of calcium, fluoride, strontium, carbonate or phosphate salts; bone repair
08/21/2003US20030158265 Embedded into an oily matrix, an expectorant (e.g., guaifenesin); a surfactant (e.g., lecithin); a suspending agent (e.g., beeswax); and a suspension medium (e.g., soybean oil)
08/21/2003US20030158264 Embedded into an oily matrix, an expectorant (e.g., guaifenesin); a surfactant (e.g., lecithin); a suspending agent (e.g., beeswax); and a suspension medium (e.g., soybean oil)
08/21/2003US20030158263 Orally administrable pharmaceutical formulation
08/21/2003US20030158261 Reducing the likelihood of side effects associated with the administration of guanfacine or angrelide by administering along with both a pH dependent and a non-pH dependent sustained release agent
08/21/2003US20030158249 Is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1 mu M.
1 ... 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 ... 2991